NorthWest Biotherapeutics Inc (NWBO)

[dmb2]

I recall a small Canadian bio several years ago pull off the uplist/RS/raise all at one time and was bought out shortly after, but there are many ways this can go. There are always issues which need to be worked out in a buyout, in this case due to the tiny size of NWBO the only one that is obvious is valuation.
I see no risk to a BP buying this technology to just shelve it because if the P3 has strong positive data as expected there will be many efforts to utilize DC science springing up and I don't think a BP will pay a hefty price to create a dead asset when their own IP clocks are running and the asset has huge potential value to its owner.
Pfizer utilized the partnership model a few times successfully in past years as did Roche and others who did not want to commit large capital outlays. In this case I agree a buyout is the preferred method assuming a valuation agreement can be reached. On the upside there is huge potential to the use of the platform in oncology. On the downside there is limited IP protection. So, a BP would need to assess how they can position DCVax in the short term for long term development. NWBO has done a good job of enabling that potential with such long term, rich data from this P3 to expand from.
I would love to be in a scientific review group meeting of a BP discussing the development needs vs the potential of this platform to be applied across the spectrum of oncology areas.

All my opinion of course, GLTA